this was a great read, thank you so much for highlighting...

this was a great read, thank you so much for highlighting it's availability.

Of particular interest to me was the analyst viewpoint on KidneyIntelX as not a competitor but potentially a diagnostic tool that could be use side-by-side with PromarkerD. 

The second key takeaway was the increased emphasis on Positive ph2 results from the Janssen collaboration very likely to lead to CDx (that's just my interpretation of reading the wording).

It would seem FDA approval is very much in the longer term given local manufacturing partner and relevant ISO certification is needed, but with over 250,000 approved labs that can support the LDT version, the US penetration is still full steam ahead. As far as I can judge, the reimbursement code is really the make or break here.

$1 target is very conservative (10% penetration) and doesn't factor in the other cakes in the oven.

The other exciting detail was an estimated 16,000 tests expected to be sold before current FY close. Very nice.